Nanobiotix SA (NBTX) 뉴스

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

PARIS and CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX –...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

Data show favorable safety and confirm injection feasibility in 12 patients with locally advanced NSCLC...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

PARIS and CAMBRIDGE, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX –...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form F-3 - Registration statement by foreign private issuers

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]